Efficacy of LAMA Added to ICS in Treatment of Asthma
Efficacy of LAMA Added to ICS in Treatment of Asthma
The purpose of this study is to evaluate the superiority of the glycopyrrolate bromide (CHF
 5259 pMDI) versus placebo on top of QVAR® pMDI, in terms of lung functions parameters, as
 well as to assess its safety.
Inclusion Criteria:

 -  History of asthma ≥ 5 years and diagnosed before 40 years old

 -  Uncontrolled asthma on low-medium doses of Inhaled CorticoSteroid (ICS) with ACQ
 (Asthma Control Questionnaire) ≥1.5

 -  Pre-bronchodilator FEV1 ≥40% and <90% of their predicted normal value

 -  Positive reversibility test

 Exclusion Criteria:

 -  Pregnant or lactating women

 -  Diagnosis of Chronic Obstructive Pulmonary Disease (COPD)

 -  Patients treated for asthma exacerbation in the 4 weeks prior to study entry

 -  Patients who are in therapy for gastroesophageal reflux disease

 -  Patients who have a clinically significant cardiovascular condition